Randomized phase III trial of erlotinib versus docetaxel as second- Or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and erlotinib lung cancer trial (DELTA)
Dive into the research topics of 'Randomized phase III trial of erlotinib versus docetaxel as second- Or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and erlotinib lung cancer trial (DELTA)'. Together they form a unique fingerprint.